Patients with recurrent or refractory solid tumors or brain tumors that are unresponsive to conventional therapy, or with no known effective therapy, will be treated. Experiments in the laboratory have shown the experimental drug RAD001C (RAD001, Everolimus) can prevent cells from multiplying. RAD001 is now being tested in diseases such as cancer, in which excessive cell multiplication needs to be stopped. The drug has been tested in adult cancer patients and has been well tolerated by subjects in these studies. It is experimental and, therefore, available in clinical trials.
Although a Phase II portion of this study was planned, it was never initiated.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
41
The drug is given orally in 28 day courses.
St. Jude Children's Research Hospital
Memphis, Tennessee, United States
To find the highest dose of RAD001 that can be given to children with refractory or relapsing solid tumors, leukemias, or brain tumors without causing severe side effects
Time frame: Within 30 days per subject
To find out if there are changes in the body's blood cells and tumor cells after treatment with RAD001
Time frame: Within 30 days per subject
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.